USP2

Across TCGA pan-cancer cohorts, USP2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated USP2 data layer compared with 18 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher USP2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated USP2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LIHC, CHOL, and UCEC are the cancer types where USP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.125	0.547	<.001	20	view →
CHOL	DFS	Median	All	0.096	0.496	.004	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	II,III,IV	1.000	0.375	.037	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

USP2–LIHC (DFS)

Open the LIHC breakdown →